



# Disclaimer

The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by **Allied Minds plc** (the "Company"). The information in the Presentation is not intended to form the basis of any contract. By attending (whether in person or by telephone) or reading the Presentation, you agree to the conditions set out below.

THIS PRESENTATION IS NOT A PROSPECTUS. The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of the Company, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract whatsoever relating to any securities.

The Presentation is provided for general information only and does not purport to contain all the information that may be required to evaluate the Company. The information in the Presentation is provided as at the date of the Presentation (unless stated otherwise) and is subject to updating, completion, revision and further verification. No reliance may be placed for any purpose whatsoever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions. To the extent permitted by law or regulation, no undertaking, representation or warranty or other assurance, express or implied, is made or given by or on behalf of the Company, or any of its parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of their respective directors, officers, partners, employees, agents, affiliates, representatives or advisors, or any other person, as to the accuracy, completeness or fairness of the information or opinions contained in the Presentation. Save in the case of fraud, no responsibility or liability is accepted by any such person for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred, however arising, directly or indirectly, from any use of, as a result of the reliance on, or otherwise in connection with, the Presentation. In addition, no duty of care or otherwise is owed by any such person to recipients of the Presentation or any other person in relation to the Presentation.

Nothing in the Presentation is, or should be relied on as, a promise or representation as to the future. The Presentation includes certain statements, estimates, opinions and projections provided by the Company in relation to strategies, plans, intentions, expectations, objectives and anticipated future performance of the Company and its subsidiaries. By their nature, such statements, estimates, opinions and projections involve risk and uncertainty since they are based on various assumptions made by the Company concerning anticipated results which may or may not prove to be correct and because they may relate to events and depend on circumstances that may or may not occur in the future and may be beyond the Company's ability to control or predict. No representations or warranties of any kind are made by any person as to the accuracy of such statements, estimates, opinions or projections, or that any of the events expressed or implied in any such statements, estimates or projections will actually occur. The Company is not under any obligation, and expressly disclaims any intention, to update or revise any such statements, estimates, opinions or projections following the date of this Presentation. No statement in the Presentation is intended as a profit forecast or a profit estimate.

Certain industry and market data contained in this Presentation has come from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry and market data contained in this Presentation comes from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice.

The Presentation is confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by its recipients to any other person for any purpose, other than with the consent of the Company. By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (ii) you have read and agree to comply with the contents of this notice.

# Allied Minds PLC – ALM.L

## Allied Minds creates next-generation companies in the high-tech and life science sectors

- Listed June 25, 2014
- Premium Listing on London Stock Exchange
- Added to FTSE 250 in early 2015

Selected for inclusion in key indices:



- FTSE 250
- FTSE MID 250
- FTSE All Share
- Global Small Cap
- FTSE 350
- FTSE 350 Low Yield

### Key Institutional Shareholders

Blackrock	Invesco
L&G	MFS
Woodford	Vanguard

### Share Price Performance

Growth since IPO in June 2014



Lead Bankers: Jefferies  
Auditors: KPMG  
Research: Numis, Jefferies



# Why Allied Minds Listed in London vs. NYC

- For our company, provided better access to capital
  - Since 2006, successfully raised capital in London
  - Concentrated group of institutional investors
- For our business, London has an established industry sector and recognized peer group
- Appropriately-sized governance levels
  - Requirements scale to size of company
- Lower cost compared to U.S.



# Our Goals

**We seek to deliver above average financial returns for our shareholders through the creation of high quality disruptive businesses**



**We have built a diversified portfolio of 22+ valuable businesses with high growth potential which address huge global markets**



**We commercialise the very best innovation at leading US universities and government labs**

**With these innovations, we create next generation businesses which are well funded and well managed, while maintaining substantial ownership positions**

**We grow our businesses into valuable assets which we believe will have out-sized returns**



# Subsidiary Overview – Life Sciences

Overview	
 <p><b>ALLIED-BRISTOL</b> Life Sciences <small>An Allied Minds Company</small></p>	<p>A jointly owned company between Allied Minds and Bristol-Myers Squibb to identify and commercialize biopharmaceutical breakthroughs at US universities and labs which can trigger mutually agreed upon preclinical exits.</p>
 <p><b>Biotectix</b> <small>An Allied Minds Company</small></p>	<p>Seeking to enable the next generation of implantable electrostimulation and sensing products through the development of proprietary, high-performance, conducting polymer materials and coatings.</p>
 <p><b>cephalogics</b> <small>An Allied Minds Company</small></p>	<p>Non-invasive, bedside brain imaging of multiple cerebrovascular regions for patients with neurological injuries.</p>
 <p><b>CRYOTRACT</b> <small>An Allied Minds Company</small></p>	<p>Suite of solutions to enable access and re-access to frozen biospecimens safely without exposing them to freeze/thaw cycles, preserving sample integrity.</p>
 <p><b>LuxCath, LLC</b> <small>An Allied Minds Company</small></p>	<p>Breakthrough catheter-based optical technology to determine tissue contact and to monitor lesion progression in cardiac ablation with a focus on atrial fibrillation ablation.</p>
 <p><b>NOVARE</b> pharmaceuticals <small>An Allied Minds Company</small></p>	<p>An innovative biotech company dedicated to treating catastrophic disease by aiding the body's own natural regenerative process through the inhibition of RHAMM-driven processes that are associated with inflammation and fibrosis</p>
 <p><b>PRECISION BIOPSY</b> <small>An Allied Minds Company</small></p>	<p>Optical imaging and biopsy device for real-time tissue characterization, diagnosis, and focal therapy of prostate cancer.</p>
 <p><b>SciFluor</b> Life Sciences <small>An Allied Minds Company</small></p>	<p>A drug discovery company developing an expanding portfolio of patented, best-in-class compounds through the strategic use of fluorine to optimize therapeutic drugs across a broad array of significant diseases.</p>
 <p><b>SOUND CURE</b> <small>An Allied Minds Company</small></p>	<p>Complete tinnitus treatment featuring customized FDA-cleared S-Tone sound therapy technology licensed from UC Irvine, providing relief through audiology clinics and a breakthrough telemedicine home-care model.</p>



# Subsidiary Overview – High Technology



## Overview

AMFi leverages its public-private partnerships to commercialize promising inventions emerging from the R&D facilities of the Department of Defense, Department of Energy and US government agencies as well as other U.S. federal research labs.

Next-generation wireless communications technologies to enhance spectrum supply, demand, and delivery for future cellular communications.

Seeking to commercialise the next generation of optical transmission capabilities to enable low latency, high throughput downlink of Low Earth Orbit originated data to terrestrial ground control stations

A cyber security platform company established to discover, incubate and commercialize emerging technologies to include IP.

Developing innovative mobile security products with context-aware and policy-based controls for the evolving cyber-operating environment.

Percipient is developing next-generation active defense products for enterprise network security. Percipient's STRONGARM product represents the first incident response platform.

Addressing the need to manage encryption across high scale and diverse environments ranging from mobile to cloud, reducing the risk of attack by incorporating the principles of quantum physics originally proven at Los Alamos National Laboratory

Seeks to make food safe from insects and pathogens through a process that does not use chemicals. This innovative disinfectant and disinfestation technology has a broad range of potential applications, including food safety, agriculture, import/export compliance, wood and waste water treatment.

Novel mixed signal analog IP for high performance low power wireless systems that improves with smaller feature size, licensed from Columbia University.

Thin film, low temperature solid oxide fuel cells for affordable and efficient power generation in portable and small stationary applications.

Next-generation Magnetoresistive Random Access Memory (MRAM) technology, offering the non-volatility of Flash and high read/write performance of DRAM and SRAM.

# Questions?



Thank You!